Yona Geffen
Chief Tech/Sci/R&D Officer bei GAMIDA CELL LTD.
Profil
Yona Geffen is currently the Vice President-Research & Development at Gamida Cell Ltd.
Prior to this, she was the Chief Executive Officer at Avraham Pharmaceuticals Ltd.
from 2011 to 2016.
She also worked as a Director-Executive Drug Development at BioLineRx Ltd.
Dr. Geffen holds graduate and doctorate degrees from Ben-Gurion University of the Negev.
Aktive Positionen von Yona Geffen
Unternehmen | Position | Beginn |
---|---|---|
GAMIDA CELL LTD. | Chief Tech/Sci/R&D Officer | 01.12.2020 |
Ehemalige bekannte Positionen von Yona Geffen
Unternehmen | Position | Ende |
---|---|---|
Avraham Pharmaceuticals Ltd.
Avraham Pharmaceuticals Ltd. BiotechnologyHealth Technology Avraham Pharmaceuticals Ltd. develops pharmaceutical products for prevention and treatment of neurodegenerative disorders. Its lead product candidate, Ladostigil is designed to provide treatment for Mild Cognitive Impairment. The firm’s product candidate is a multifunctional compound that combines neuroprotective mechanisms: reducing oxidative stress and microglial activation, and inhibiting proinflamtory cytokines. The company was founded in 2010 by David Warshawsky and is headquartered in Yavneh, Israel. | Chief Executive Officer | 01.12.2016 |
BIOLINERX LTD. | Corporate Officer/Principal | - |
Ausbildung von Yona Geffen
Ben-Gurion University of the Negev | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 2 |
---|---|
BIOLINERX LTD. | Health Technology |
GAMIDA CELL LTD. | Health Technology |
Private Unternehmen | 1 |
---|---|
Avraham Pharmaceuticals Ltd.
Avraham Pharmaceuticals Ltd. BiotechnologyHealth Technology Avraham Pharmaceuticals Ltd. develops pharmaceutical products for prevention and treatment of neurodegenerative disorders. Its lead product candidate, Ladostigil is designed to provide treatment for Mild Cognitive Impairment. The firm’s product candidate is a multifunctional compound that combines neuroprotective mechanisms: reducing oxidative stress and microglial activation, and inhibiting proinflamtory cytokines. The company was founded in 2010 by David Warshawsky and is headquartered in Yavneh, Israel. | Health Technology |